⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19748863 | 0.85 | — | — | |
| SCHEMBL23270103 | 0.82 | — | — | |
| SCHEMBL21618324 | 0.79 | — | — | |
| SCHEMBL16244555 | 0.78 | FPR2 (0.30) | — | |
| SCHEMBL14786478 | 0.77 | TSHR (0.41) | — | |
| SCHEMBL21618345 | 0.76 | — | — | |
| SCHEMBL21626321 | 0.76 | EPHX2 (0.33) | — | |
| SCHEMBL20541959 | 0.74 | IDO1 (0.31) | — | |
| SCHEMBL19953452 | 0.73 | — | — | |
| SCHEMBL22614102 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149239-A1 | HETEROAROMATIC CYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2024-07-18 | — | — | WO | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| US-20240109905-A1 | 4-ALKOXY-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| EP-3810116-B1 | NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4271387-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF | Immunext, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023205507-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC | 2020-06-25 | — | — | US | disclosed |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3612517-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Tempest Therapeutics, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2019204180-A1 | NOVEL [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-24 | — | — | WO | disclosed |
| EP-3510033-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | Novartis AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2018195123-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018047081-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2018-03-15 | — | — | WO | disclosed |